Emerging research from the recent Society of Interventional Radiology (SIR) conference suggests the combination of transarterial radioembolization (TARE) and immunotherapy may offer improved three-year survival outcomes for patients with breast cancer and liver metastases.

Read the full article on diagnosticimaging.com